UGT1A1＊28基因多态性与小细胞肺癌

UGT1A1 ＊ 28 polymorphism and small cell lung cancer

尿苷二磷酸葡糖醛酸转移酶1A1（uridine diphosphate glucuronosyl transferase 1A1，UGT1A1）是伊立替康（Irinotecan，CPT-11）活性产物的主要代谢酶，其活性与CPT-11的疗效和不良反应均密切相关，而UGT1A1＊28基因多态性可显著降低UGT1A1酶的表达与活性。IP（伊立替康＋顺铂）方案是广泛期小细胞肺癌的一线化疗方案，UGT1A1＊28基因多态性可影响IP方案的疗效及不良反应，检测UGT1A1＊28基因多态性对于指导小细胞肺癌患者的个体化治疗具有一定的临床意义。

UGT1A1 is the main metabolic enzyme for active product of Irinotecan （CPT-11）. Its activity is closely related to the efficacy and adverse reactions of CPT-11. However, UGT1A1 ＊ 28 gene polymorphism can significantly reduce the expression and activity of UGT1A1 enzyme. IP （irinotecan＋ eisplatin） program is the first-line chemotherapy of extensive stage small cell lung cancer, UGT1A1 ＊ 28 gene polymorphism may affect the efficacy and adverse reactions of IP program. So detecting UGT1A1 ＊ 28 gene polymorphism can guide individualized treatment of patients with small cell lung cancer.